Solanezumab: Alzheimer's Drug But Requires Early Diagnosis
This calls for major and urgent improvements in the methods used to identify Alzheimer's patients if the field is to take advantage of medications, which can halt or inhibit the mental decline rate.
The announcement by Eli Lilly was received well by scientists as the drug would go a long way in slowing the rate the Alzheimer's would damage the patient brain. Scientists had earlier indicated that the trial stage of Lilly's solanezumab was about done on patients who already tested and had Alzheimer's, hence would be expected to suffer the loss of brain power. To effectively manage the disease, means have been formulated to diagnose people with high risk of developing the complication, earlier before their brain is damaged.
According to Professor from Manchester University, there is an urgent need for studies on the disease, which should correspond with the announcement by the pharmaceutical giant. Professor Mann indicates that the studies would complement the effort by the solanezumab.
The announcement by Eli Lilly come at a point where the accuracy level of Alzheimer's diagnosis tests is discouraging, with records indicating 25% of the disease diagnosis reports are incorrect. Top researchers highlight this, as a challenge to develop reliable diagnosis methods.
The sweet news by Lilly's solanezumab raises hopes of more advancement in the field and also the development of medication, which has the ability to delay the disease, also inhibiting the severe impacts caused by the disease.
Alzheimer's disease is caused by protein accumulation, for instance, amyloid protein in the brain. The accumulated protein in the brain forms plaques or clumps that scientists indicate are the cause of confusion, memory loss and disorientation.
Solanezumab binds to the abeta, which are specific molecules, which forms the brain amyloid. This can be the explanation for the medication functioning. The medication has the ability to slow Alzheimer's when in the mild state. The medication will only be boosted by early diagnosis and accurate results, which currently leaves a lot to be desired.
Lilly Indicates the research is not done yet; new developments are expected when the firm scientists and researchers conduct the second test trial of the medication of a patient diagnosed with early and mild Alzheimer's. There are positive prospects that these developments are on the track of the development of Alzheimer's disease medication. Scientists also say the announcement made by Lilly is exciting as it validates the amyloid hypothesis
Solanezumab medication hopes also come at the point where the diagnosis for Alzheimer's has risen to around 225,000 in the UK, an indication of a dire need for a breakthrough in this field.